Defining high-risk CLL: known and emerging mutations

Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, discusses the criteria used to define high-risk disease in chronic lymphocytic leukemia (CLL), commenting on their impact on treatment decisions. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.